Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATAI LIFE SCIENCES N.V.

(ATAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Atai Life Sciences N : Credit Suisse Starts Atai Life Sciences at Outperform with $25 PT, Notes Diversified Platform Approach to NeuroPsych Drug Development

07/13/2021 | 09:14am EDT


ę MT Newswires 2021
All news about ATAI LIFE SCIENCES N.V.
09/21ATAI LIFE SCIENCES N : Unit Starts Dosing in Phase 1/2a Trial of Ibogaine in Opioid Use Di..
MT
09/21ATAI LIFE SCIENCES N : DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogain..
AQ
09/15ATAI LIFE SCIENCES N : Increases Loan in Principal by US$6m to Support IntelGenx's Graduat..
AQ
09/14ATAI LIFE SCIENCES N : ' Perception Neuroscience Initiates Phase 2a Study of PCN-101 to Tr..
MT
09/14ATAI LIFE SCIENCES N : Perception Neuroscience initiates Phase 2a study of PCN-101 (R-keta..
AQ
09/09atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeuti..
GL
09/09Atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeuti..
CI
09/03ATAI LIFE SCIENCES N : to Participate in Upcoming September Investor Conferences
AQ
09/01ATAI LIFE SCIENCES N : Jefferies Starts Atai Life Sciences at Buy with $27 Price Target
MT
08/20ATAI LIFE SCIENCES N : Management's Discussion and Analysis of Financial Condition and Res..
AQ
More news
Analyst Recommendations on ATAI LIFE SCIENCES N.V.
More recommendations
Financials (USD)
Sales 2021 18,1 M - -
Net income 2021 -120 M - -
Net cash 2021 383 M - -
P/E ratio 2021 -18,9x
Yield 2021 -
Capitalization 2 477 M 2 477 M -
EV / Sales 2021 116x
EV / Sales 2022 -
Nbr of Employees 35
Free-Float 90,3%
Chart ATAI LIFE SCIENCES N.V.
Duration : Period :
Atai Life Sciences N.V. Technical Analysis Chart | ATAI | NL0015000DX5 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 16,00 $
Average target price 29,10 $
Spread / Average Target 81,9%
EPS Revisions
Managers and Directors
Florian Brand Chief Executive Officer
Gregory L. Weaver Chief Financial Officer
Srinivas G. Rao Chief Scientific Officer
Rolando GutÝerrez-Esteinou Chief Medical Officer
Alexis Marc Joel Louis de Rosnay Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ATAI LIFE SCIENCES N.V.0.00%2 477
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353